Patent intelligence · US
US 7855191
Agent having a destructive effect on malignant tumors and method for the production thereof
Agent having a destructive effect on malignant tumors and method for the production thereof
Patent details — US 7855191
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 21, 2010
- Expiration
- Dec 16, 2030
- Applicant
- C.Y.L. Pharmazeutika GmbH
- Claims
- 21
- CPC classes
- A61K, A61K31/05, A61K31/194, A61K31/198
Quick answer
US 7855191 (Agent having a destructive effect on malignant tumors and method for the production thereof) is held by C.Y.L. Pharmazeutika GmbH. Status: granted. Granted Dec 21, 2010. Expires Dec 16, 2030 (4 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- C.Y.L. Pharmazeutika GmbH
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K31/05, A61K31/194, A61K31/198, A61K31/341, A61K31/351
More from C.Y.L. Pharmazeutika GmbH
Related pharmaceutical patents in our USPTO index.
-
US 12310943
Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders
granted -
US 12297182
Compositions comprising an urolithin compound
granted -
US 12226455
Medical composition for treating cardiac wasting and cachexia
granted -
US 12220424
Compositions comprising nicotinamide riboside and a urolithin
granted -
US 12109190
Urolithins as immune response enhancers
granted -
US 12036205
Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders
granted -
US 12030863
Prodrugs of urolithins and uses thereof
granted -
US 11969408
Method for improving mitophagy in subjects
granted
Frequently asked questions
What is US patent 7855191?
US 7855191 (Agent having a destructive effect on malignant tumors and method for the production thereof) is held by C.Y.L. Pharmazeutika GmbH. Status: granted. Granted Dec 21, 2010. Expires Dec 16, 2030 (4 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7855191?
C.Y.L. Pharmazeutika GmbH is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 60 pharmaceutical patents for this assignee.
When does US 7855191 expire?
Our index shows an expiration date of Dec 16, 2030 (4 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.